All In Biotech

Drug Trial Radar · NCT05593575

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 305 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

305

Actual

Start

Mar 22, 2023

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in reduction in proteinuria in patients with diabetic kidney disease with valsartan as the comparator, and determine the recommended dose.

Conditions

  • Diabetic Kidney Disease

Interventions

  • SPH3127+SPH3127matching placebo+valsartan matching placeboDrug

    1 tablet of SPH3127 (50 mg) ,3 tablets of SPH3127 (50mg)matching placebo, 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks

  • SPH3127+SPH3127matching placebo+valsartan matching placeboDrug

    2 tablet of SPH3127 (50 mg) ,2 tablets of SPH3127 (50mg)matching placebo, 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks

  • SPH3127+valsartan matching placeboDrug

    4 tablet of SPH3127 (50 mg) , 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks

  • SPH3127 matching placebo+valsartanDrug

    4 tablets of SPH3127 (50mg)matching placebo, 1 capsule of valsartan, orally, once daily for 12 consecutive weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in UACRTime frame: at the end of Week 12 of treatment

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgeng Hospital

    Beijin, China

  • Beijing Anzhen Hospital,Capital Medical University

    Beijing, China

  • Beijing Tiantan Hospital,Capital Medical University

    Beijing, China

  • Beijing Tongren Hospital

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Chengdu Seventh People's Hospital

    Chengdu, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Shunde Hospital of Southern Medical University

    Foshan, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, China

  • Huizhou First Hospital

    Huizhou, China

  • Qilu Hospital of Shandong University

    Jinan, China

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, China

  • Ningbo No.2 Hospital

    Ningbo, China

  • Affiliated Zhongshan Hospital of Fudan University,Qingpu Branch

    Shanghai, China

  • Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Shanghai Fengxian District Central Hospital

    Shanghai, China

  • Shanghai Minhang District Central Hospital

    Shanghai, China

  • Sheng Jing Hospital of China Medical University

    Shenyang, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, China

  • The Seventh Affiliated Hospital,Sun Yat-sen University

    Shenzhen, China

  • Second Hospital of Shanxi Medical University

    Taiyuan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China

    Fuzhou, Fujian, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital,Sun Yat sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • The Third Hospital of Wuhan

    Wuhan, Hubei, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Second Norman Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • The First People's Hospital of Yinchuan

    Yinchuan, Ningxia, China

  • Qinghai University Affiliated Hospital

    Xining, Qinghai, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, China

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.